Japan CAR-T Cell Therapy Market, By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (Brexucabtagene Autoleucel), Breyanzi (Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel), Others), By Tumor Type (Hematological Malignancies, Solid Tumors), By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationJapan CAR-T Cell Therapy Market, By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (Brexucabtagene Autoleucel), Breyanzi (Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel), Others), By Tumor Type (Hematological Malignancies, Solid Tumors), By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma
| Forecast Period | 2025-2029 |
| Market Size (2023) | USD 66.06 million |
| CAGR (2024-2029) | 13.44% |
| Fastest Growing Segment | Hematological Malignancies |
| Largest Market | Hokkaido |
Market Overview
Japan CAR-T Cell Therapy Market stood at USD 66.06 million in 2023 and is expected to grow at a robust rate of 13.44% during the forecast period. This can be ascribed to the growing prevalence of different types of cancer and need to find an effective treatment for the same. Cancer continues to be a significant health challenge, necessitating innovative approaches to treatment. Among the groundbreaking therapies that have emerged in recent years, Chimeric Antigen Receptor T-cell (CAR-T) therapy stands out as a revolutionary treatment option. With its ability to harness the patient's own immune system to target and destroy cancer cells, CAR-T therapy has garnered immense attention in Japan.
The introduction of CAR-T cell therapy has opened new avenues in cancer treatment in Japan. The Japanese CAR-T cell therapy market has witnessed significant growth due to its potential to provide a curative treatment option for patients who have exhausted other found at therapies.
Key Market Drivers
High Incidence of Hematological Cancers Driving the Japan CAR-T Cell Therapy Market
Hematological cancers, also known as blood cancers, encompass a group of malignancies that originate in the blood-forming tissues, such as bone marrow and lymphatic system. These cancers include leukemia, lymphoma, and myeloma, and are characterized by the rapid and uncontrolled growth of abnormal blood cells. In Japan, like many other parts of the world, hematological cancers have been a significant health concern, contributing to substantial morbidity and mortality rates. The emergence of CAR-T cell therapy as a promising treatment avenue has garnered immense attention, offering renewed hope for patients battling these challenging diseases.
This personalized form of immunotherapy involves reprogramming a patient's own T-cells to recognize and attack cancer cells with precision. The therapy begins with the extraction of T-cells from the patient's blood, which are then genetically engineered to express chimeric antigen receptors specific to the patient's cancer type. These modified T-cells are then infused back into the patient's body, where they target and destroy cancer cells.
Rising Healthcare Expenditure Driving the Japan CAR-T Cell Therapy Market
Japan's healthcare expenditure has been steadily increasing over the years due to factors like an aging population and higher medical costs. This rising expenditure has created a more favorable environment for the adoption of advanced treatments, including CAR-T cell therapy. Patients and healthcare providers are more willing to explore innovative solutions when faced with life-threatening conditions, leading to increased demand for these therapies.
Key Market Challenges
High Costs
CAR-T cell therapy is associated with high production costs due to its personalized nature and complex manufacturing process. This raises concerns about accessibility and affordability for patients.
Infrastructure and Logistics
The specialized infrastructure required for CAR-T therapy production, storage, and administration presents logistical challenges for healthcare facilities in Japan.
Patient Eligibility Criteria
Identifying suitable patients for CAR-T therapy based on eligibility criteria and disease progression remains a critical consideration to maximize its benefits.
Long-Term Safety and Efficacy
Key Market Trends
Technological Advancements
Innovative advancements in cell culture techniques, bioreactors, and cell expansion technologies have contributed to the scalability of CAR-T cell therapy production. These developments have enabled the production of larger batches of high-quality CAR-T cells, making the therapy more accessible to a broader patient population. The integration of bioinformatics and data analytics has enabled researchers to better understand the complex interactions between CAR-T cells and cancer cells. This knowledge has led to the design of CAR-T constructs that exhibit enhanced specificity and potency, thereby improving treatment outcomes.
Segmental Insights
Drug Type
In 2023, the CAR-T Cell Therapy market was dominated by the Yescarta (Axicabtagene Ciloleucel) segment and is predicted to continue expanding over the coming years. Yescarta (Axicabtagene Ciloleucel) stands out as a pioneering treatment that harnesses the power of the immune system to combat cancer cells.
Tumor Type Insights
In 2023, the CAR-T Cell Therapy market was dominated by the Hematological Malignancies segment and is predicted to continue expanding over the coming years.
Regional Insights
The Hokkaido region has established itself as the leader in the Japan CAR-T Cell Therapy Market.
Recent Developments
- In September 2022,Bristol-Myers Squibb Company announced that Abecma (idecabtagene violence), achimeric antigen receptor (CAR) T cell therapy targeting B-cell maturationantigen (BCMA), received approval from Japan's Ministry of Health, Labour andWelfare. This treatment is intended for adult patients dealing with relapsed orrefractory (R/R) multiple myeloma.
- In August 2023, TheJanssen Pharmaceutical Companies of Johnson & Johnson made an announcementthat the U.S. Food and Drug Administration (FDA) has granted acceleratedapproval to TALVEYâ„¢ (talquetamab-tgvs). This is a unique bispecific antibodydesigned to treat adult patients dealing with relapsed or refractory multiplemyeloma. These patients must have undergone at least four previous lines oftreatment, including a proteasome inhibitor, an immunomodulatory agent, and ananti-CD38 antibody. This approval is granted based on the rapid response rateand the sustainability of the response. The ongoing approval for this specificuse will depend on confirming its clinical benefits through further trials.
Key Market Players
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc.
- Johnson & Johnson KK
- Bristol-Myers Squibb
- Gilead Sciences
| By Product Type | Tumor Type | By Indication | By Treatment Type | By Targeted Antigen | By End User | By Region |
|
|
|
|
|
|
|
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy